Supriya Lifescience reports Q1 FY27 results with Revenue growing by 30.8% YoY

Supriya Lifescience reports Q1 FY27 results with Revenue growing by 30.8% YoY​

Supriya Lifescience Ltd., a global cGMP-compliant manufacturer specializing in APIs across various therapeutic segments including anti-histamine, vitamin, and anti-asthmatic products, reported its unaudited financial results for the quarter ended June 30, 2026. The company has a presence in over 120 countries globally.

The Q1 FY27 results showed significant revenue growth but also highlighted shifts in profitability metrics compared to Q1 FY26.

Key Consolidated Financial Highlights
Supriya Lifescience saw its revenues rise substantially, although the Profit After Tax (PAT) metric decreased year-over-year. The company continues to focus on expanding its product portfolio and strengthening manufacturing capacities.

The consolidated financial performance across Q1 FY27 and Q1 FY26 is summarized below:


Operational and Segment Performance
In Q1 FY27, the company's revenue grew by 30.8% compared to the Rs 145.07 crore recorded in Q1 FY26. While EBITDA for Q1 FY27 was Rs 47.46 crore (with a 25.0% margin), down from Rs 51.70 crore and a 35.6% margin in the previous period, PAT stood at Rs 24.04 crore, reflecting a PAT Margin of 12.7% against 24.0% in Q1 FY26.

Segment-wise performance showed the Anesthetic segment contributing 48% of revenue in Q1 FY27, compared to 53% in Q1 FY26. Vitamins contributed 17% of revenue in Q1 FY27, up from 11% of revenue in Q1 FY26.

Geographically, Asia was the largest market contributor, accounting for 39% of revenue in Q1 FY27, an increase from 32% in Q1 FY26. Europe contributed 35%, LATAM accounted for 20%, while North America and other markets each contributed 3%. The export contribution stood at 81% of the total revenue for the quarter.

Manufacturing Expansion and R&D Focus
The company maintained a capacity utilization rate of 70% in Q1 FY27, matching levels reported in FY25, after having been 74% in FY26. The manufacturing footprint continues to expand, with a total reactor capacity of 932 KLPD across its blocks.

The Ambernath facility has now commissioned its finished dosage manufacturing capabilities, which cover tablets, capsules, liquids, nasal, inhalation, and injections. Validation and registration batches are currently underway for dossier submissions at this site.

Strengthening R&D remains a core focus, with over 68 scientists working on API and formulation process development. The company has also established two new R&D centers in Ambernath and Lote, while planning to add three to four products annually.

The product pipeline is progressing, highlighted by the Cardiovascular segment launching in Q3 FY26 and contributing revenue in Q4 FY26. Furthermore, the ADHD product is seeing strong demand from LATAM and Europe and is actively scaling up production. The Liquid Anesthetic product has been commercialized and is currently receiving steady monthly supplies. Supriya Lifescience Ltd. plans approximately two launches each in both the Anesthetic and ADHD segments during FY27 to deepen its product offering and support future growth.

Dr. Satish Wagh, Executive Chairman and Whole-Time Director, commented on the results, stating that Q1 FY27 reflects continued momentum driven by strong revenue growth and a diversified global presence. He noted that the company remains focused on expanding its portfolio, strengthening R&D and manufacturing, and scaling new products across key therapeutic segments to achieve sustainable long-term growth.

SUPRIYA Stock Price Movement​

Shares of Supriya Lifescience Limited slipped by 2.17% on Thursday, settling at ₹813.50. The equity traded within a range of ₹808.5 to ₹859.6, with the stock concluding its session after 520,083 shares were transacted.